BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBDetailed data affirm ivonescimab tops Keytruda in NSCLC trial. More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc.,... Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
BioWorld: The Daily Biopharmaceutical News Source
WEBBiopharma financings near $78B, almost double last year’s value. Biopharma financing activity surged in the first eight months of 2024, reaching $77.5 billion, a 91.25% increase from the $40.52 billion raised during the same period in 2023. August saw a slight dip in funding, with $3.48 billion raised compared to $3.71 billion in July.
Boston Scientific buying Devoro Medical for $269M ... - BioWorld
WEBBoston Scientific Corp. grabbed the remaining shares of Devoro Medical Inc. and its Wolf thrombectomy platform in a transaction valued at $269 million. Freemont, Calif.-based Devoro stands to gain an additional $67 million if the company achieves undisclosed clinical and regulatory milestones. Boston Scientific began investing in Devoro in 2019 and currently holds 16% of Devoro. The deal, the ...
Rhythm wins first FDA approval for obesity drug Imcivree
WEBNov 30, 2020 · Rhythm Pharmaceuticals Inc., a company developing medicines for rare genetic disorders of obesity, has won FDA approval for its first product, Imcivree (setmelanotide), following a priority review. The drug is designed to restore a biological pathway that, when disrupted, can lead to constant hunger. The approval covers the treatment of three types of ultrarare early onset obesity tied to pro ...
New potential broad-spectrum fungicides discovered
WEBSep 23, 2020 · A Chinese study has discovered that very long-chain fatty acids (VLCFAs) mediate septin organization in pathogenic fungi and that VLCFA biosynthesis represents a new target for controlling pathogenic fungi, which could lead to the development of new fungicides for use in plants and humans. New fungal disease targets are urgently required due to the rapidly increasing global problem of ...
Financings - BioWorld
WEBSep 9, 2024 · Biopharma financings near $78B, almost double last year’s value. Biopharma financing activity surged in the first eight months of 2024, reaching $77.5 billion, a 91.25% increase from the $40.52 billion raised during the same period in 2023. August saw a slight dip in funding, with $3.48 billion raised compared to $3.71 billion in July.
Organoids making their US clinical debut with CIDP drug
WEBJul 15, 2022 · Organoids making their US clinical debut with CIDP drug. July 15, 2022. By Nuala Moran. The use of organoids in preclinical research has reached a tipping point, with U.S. FDA approval of the first drug to enter clinical trials on the basis of efficacy data derived only from these advanced cell models. BioWorld BioWorld MedTech Regulatory U.S.
China - BioWorld
WEB2 days ago · Sep. 3, 2024. By Marian (YoonJee) Chu. No Comments. Jacobio Pharmaceuticals Group Co. Ltd. out-licensed rights for two lung cancer assets in China to Shanghai Allist Pharmaceuticals Co. Ltd. through a potential ¥900 million (US$126.4 million) deal. Beijing-headquartered Jacobio said Aug. 30 that it …
Biopharma financings hit $47B in Q1, marking second-highest …
WEBApr 18, 2024 · Biopharma firms amassed a total of $47.07 billion in the first quarter of 2024, the second-highest quarter recorded by BioWorld since 2011, trailing only behind $48.18 billion raised in 2Q20. This robust fundraising was driven by exceptional performances in IPOs, follow-ons and public/other financings, as well as …
Supranatural: Synteins being the platform, Abiologics nets $50M
WEBJuly 23, 2024. By Randy Osborne. With $50 million in hand from Flagship Pioneering, Abiologics Inc. is pairing generative artificial intelligence with high-throughput chemical protein synthesis to attack oncology and immunology indications with Synteins, synthetic proteins that represent a new class of programmable medicines.
Skip to content